Mcure Biosciences

Mcure Biosciences is a South Korean biotechnology company focused on developing innovative therapies for cancer and fibrotic diseases by targeting the Transforming Growth Factor-beta (TGF-beta) signaling pathway. The company's lead programs utilize proprietary small molecule inhibitors and peptide-based approaches to modulate the tumor microenvironment and inhibit the progression of fibrosis in organs such as the liver and lungs. Mcure Biosciences aims to overcome the limitations of current TGF-beta inhibitors by enhancing selectivity and reducing systemic toxicity. The company is currently advancing its lead candidate through early-stage clinical trials while maintaining a robust preclinical pipeline targeting high-unmet-need indications like pancreatic cancer and NASH.